PRODUCT INFORMATION



BIBF 0775

Item No. 37777

CAS Registry No.: 334951-90-5

Formal Name: (3Z)-N-ethyl-2,3-dihydro-N-methyl-2-oxo-3-

[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]


methylene]-1H-indole-6-carboxamide

MF: $C_{31}H_{34}N_4O_2$ FW: 494.6 **Purity:** ≥98%

 λ_{max} : 283, 387 nm UV/Vis.:

Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

BIBF 0775 is supplied as a solid. A stock solution may be made by dissolving the BIBF 0775 in the solvent of choice, which should be purged with an inert gas. BIBF 0775 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of BIBF 0775 in these solvents is approximately 2, 5, and 10 mg/ml, respectively.

Description

BIBF 0775 is an inhibitor of TGF- β receptor type 1 (ALK5; IC₅₀ = 34 nM).¹ It is selective for ALK5 over VEGFR2 and PDGFR α (IC₅₀s = 1,447 and 890 nM, respectively), as well as a panel of 30 other kinases at $1 \,\mu\text{M}.^{1,2}$ BIBF 0775 inhibits the phosphorylation of SMAD2 and SMAD3 in HaCaT cells (EC $_{50}$ = 105 nM) and is not cytotoxic to HaCaT cells (IC₅₀ = >1,000 nM).¹

References

- 1. Roth, G.J., Heckel, A., Brandl, T., et al. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI). J. Med. Chem. 53(20), 7287-7295 (2010).
- Roth, G.J., Heckel, A., Colbatzky, F., et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 52(14), 4466-4480 (2009).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 06/02/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM